Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment

Key Takeaways

• Spinogenix launches CLARITY Phase 2b/3 adaptive trial evaluating SPG601 in male patients with Fragile X Syndrome
• SPG601 is a first-in-class oral tablet targeting BK channels to restore synaptic function in neurological disorders
• The trial represents a significant advancement in Fragile X Syndrome treatment, addressing a rare genetic condition with limited therapeutic options

---

LOS ANGELES, April 23, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical company, has announced the initiation of CLARITY, a Phase 2b/3 adaptive clinical trial evaluating SPG601 for the treatment of Fragile X Syndrome (FXS) in male patients.

Revolutionary Approach to Fragile X Syndrome

SPG601 represents a breakthrough in neurological therapeutics as a first-in-class, oral tablet specifically designed to modulate large-conductance, calcium-activated potassium (BK) channels. This novel mechanism aims to correct synaptic dysfunction, a hallmark of Fragile X Syndrome and other neurodevelopmental disorders.

Fragile X Syndrome affects approximately 1 in 4,000 males and is the most common inherited cause of intellectual disability and autism spectrum disorder. The condition results from mutations in the FMR1 gene, leading to synaptic abnormalities that impair cognitive function and behavioral development.

Clinical Trial Significance

The CLARITY trial’s adaptive design allows for protocol modifications based on interim data analysis, potentially accelerating the path to regulatory approval. This approach is particularly valuable in rare disease research, where patient populations are limited and traditional trial designs may be less efficient.

Spinogenix’s focus on synaptic restoration through BK channel modulation represents a targeted approach to addressing the underlying pathophysiology of Fragile X Syndrome, rather than merely managing symptoms.

Market Impact and Patient Implications

Currently, no FDA-approved treatments specifically target the core symptoms of Fragile X Syndrome. Existing therapies primarily address associated behavioral symptoms through off-label use of psychiatric medications.

The successful development of SPG601 could establish Spinogenix as a leader in the rare neurological disease space, potentially opening pathways for treating other synaptic dysfunction disorders. For families affected by Fragile X Syndrome, this trial offers hope for the first targeted therapy addressing the condition’s underlying mechanisms.

---

Frequently Asked Questions

What does this trial mean for Fragile X Syndrome patients?

The CLARITY trial offers the first potential targeted therapy for Fragile X Syndrome, addressing underlying synaptic dysfunction rather than just managing symptoms. If successful, SPG601 could become the first FDA-approved treatment specifically for FXS.

When will SPG601 be available to patients?

SPG601 is currently in Phase 2b/3 trials. If successful, the adaptive trial design could accelerate development, but regulatory approval would likely take several years. Patients may access the drug through expanded access programs before full approval.

How does SPG601 differ from current Fragile X treatments?

Unlike current off-label psychiatric medications that manage behavioral symptoms, SPG601 targets BK channels to restore synaptic function at the cellular level, potentially addressing the root cause of Fragile X Syndrome rather than just symptoms.